Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance

被引:19
作者
Lu, JF
Gries, JM
Verotta, D
Sheiner, LB
机构
[1] Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94143 USA
关键词
Bayes estimates; limit of quantification; NONMEM; compliance; measurement error; population PK-PD;
D O I
10.1023/A:1011582713692
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For single-dose concentration-time data collected in clinical trials to be useful for explanatory pharmacokinetic (PK) or pharmacokinetic-pharmacodynamic (PK-PD) analyses, the following two assumptions on the data must hold: (i) the times of the concentration (PK) observations are known, and (ii) the patient's recent past dosing history (times and amounts) is known. If either (or both) of these assumptions does not hold, and data analysis proceeds as if it did, biased estimates may result. Assumption (i) usually does hold as study personnel observe and record PK sampling times. Assumption (ii) is a problem when, as is often the case for outpatient studies, one must rely on patient recall for past dosing history. This paper presents a technique to avoid assumption (ii) by identifying for deletion those PK observation occasions likely exhibiting unreliable preceding dose histories. To so identify occasions, a Bayes objective function (posterior density) for the data is maximized in its parameters for each individual. The likelihood factor of this function is a mixture pharmacostatistical model expressing the likelihood of the observed concentration(s) tinder three mutually exclusive events: the prescribed dose preceding the occasion was not taken at all (NT), the prescribed dose was taken at the specified time (T), or the prescribed dose was taken at an unspecified time (U). Suspect observations are identified as those whose maximum corresponding likelihood component is other than T. The approach as defined here relies on the following assumptions in addition to (i): (ii) population PK (i.e., the distribution of PK parameters in the population being sampled) is known, at least approximately, (iii) PK samples (at least 1 or 2 per occasion) are available, (iv) doses taken are of the stated magnitude, and (v) the drug has a short half-life. Simulations reveal that especially when more than one PK sample is available per study occasion, the methodology chooses a set of PK observations that should perform better in subsequent explanatory analyses, or as a basis for estimating individual PK parameters, than do other simpler methods.
引用
收藏
页码:343 / 362
页数:20
相关论文
共 17 条
[1]   TOBIT MODELS - A SURVEY [J].
AMEMIYA, T .
JOURNAL OF ECONOMETRICS, 1984, 24 (1-2) :3-61
[2]  
Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629
[3]   Identification of causal effects using instrumental variables - Reply [J].
Angrist, JD ;
Imbens, GW ;
Rubin, DB .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1996, 91 (434) :468-472
[4]  
BEAL SL, 1998, NONMEM USERS GUIDE
[5]  
DUDLEY MN, 1995, J INFECT DIS S2, V171, P99
[6]  
Goetghebeur E, 1998, STAT MED, V17, P341, DOI 10.1002/(SICI)1097-0258(19980215)17:3<341::AID-SIM766>3.0.CO
[7]  
2-X
[8]   A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter [J].
Hammer, SM ;
Katzenstein, DA ;
Hughes, MD ;
Gundacker, H ;
Schooley, RT ;
Haubrich, RH ;
Henry, WK ;
Lederman, MM ;
Phair, JP ;
Niu, M ;
Hirsch, MS ;
Merigan, TC ;
Blaschke, TF ;
Simpson, D ;
McLaren, C ;
Rooney, J ;
Salgo, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) :1081-1090
[9]   Discrimination between rival dosing histories [J].
Jonsson, EN ;
Wade, JR ;
Almqvist, G ;
Karlsson, MO .
PHARMACEUTICAL RESEARCH, 1997, 14 (08) :984-991
[10]   ESTIMATING COMPLIANCE TO STUDY MEDICATION FROM SERUM DRUG LEVELS - APPLICATION TO AN AIDS CLINICAL-TRIAL OF ZIDOVUDINE [J].
LIM, LLY .
BIOMETRICS, 1992, 48 (02) :619-630